Breaking News, Collaborations & Alliances

Ajinomoto, Exelixis Enter ADC Partnership

Exelixis will have the right to use the AJICAP technology to advance multiple ADCs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ajinomoto has entered a license agreement with Exelixis to incorporate AJICAP, Ajinomoto’s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ anti-body drug conjugate (ADC) programs. Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Utilizing its network of biotherapeutics collaborations, the comp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters